Oral treatment of ichthyosis by the cytochrome P-450 inhibitor liarozole

British Journal of Dermatology

Volumn 136, Issue 1, 1997, Pages 71-75

  Lucker, G P H ^a   Heremans, A M C ^b   Boegheim, P J ^c   Van De Kerkhof, P C M ^a   Steijlen, P M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c Janssen Cilag BV Netherlands   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; IMIDAZOLE DERIVATIVE; LIAROZOLE; RETINOID;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRY EYE; EPIDERMIS; HUMAN; ICHTHYOSIS; IMMUNOHISTOCHEMISTRY; KERATINIZATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURITUS;

EID: 0031021596     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1997.tb08749.x     Document Type: Article

References (18)

1. Dowling JE, Wald G. The biological function of vitamin A acid. Proc Natl Acad Sci USA 1960; 46: 587-608.
2. Chytil F. Retinoic acid: biochemistry, pharmacology, toxicology and therapeutic use. Pharmacol Rev 1984; 36: 93-100.
3. Wolf G. Multiple functions of vitamin A. Physiol Rev 1984; 64: 873-937.
4. Pilkington T, Brogden RN. Acitretin. A review of its pharmacology and therapeutic use. Drugs 1992; 43: 597-627.
5. Blanchet-Bardon CI, Nazarro V, Rognus C, Geiger JM, Puissant A. Acitretin is the treatment of severe disorders of keratinization. Results of an open study. J Am Acad Dermatol 1991; 24: 982-6.
6. Di Giovanni JJ, Helfgott RK, Gerben LH. Extraspinal tendon and ligament calcification associated with long-term therapy with etretinate. N Engl J Med 1986; 315: 1177-82.
7. Baden HP, Buxuan MM, Weinstein GD. Treatment of ichthyosis with isotretinoin. J Am Acad Dermatol 1982; 6: 716-20.
8. Ellis CN, Voorhees JJ. Etretinate therapy. J Am Acad Dermatol 1987; 16: 267-91.
9. Wauwe J van, Coene MC, Goossens J et al. Effects of cytochrome P450 inhibitors on the in vivo metabolism of all trans-retinoic acid in rats. J Pharmacol Exp Ther 1990; 252: 365-9.
10. Bruynseels J, Coster R de, Rooy P van et al. R 75251, a new inhibitor of steroid biosynthesis. Prostate 1990; 16: 345-57.
11. Coster T de, Coene MC, Wauwe J van et al. Assessment of the multiple-dose pharmacokinetics of liarozole fumarate and its effect on the endocrine system in healthy male subjects. Clinical Research Report. Janssen Research Foundation. N 106593/1 May 1994.
12. Doncker P, Deree J, Degreef H. Inhibition of the metabolism of endogenous retinoic acid as treatment for severe psoriasis: an open study with oral liarozole. Br J Dermatol 1995; 133: 426-32.
13. Lucker GPH, van de Kerkhof PCM, Castelijns FACM, van Dijk MR, Schalkwijk LJM, Steijlen PM. Topical treatment of ichthyoses with 13-cis retinoic acid. A clinical and immunohistochemical study. Eur J Dermatol 1995; 5: 566-71.
14. Fritsch PO. Retinoids in psoriasis and disorders of keratinization. J Am Acad Dermatol 1992; 27: S8-14.
15. Steijlen PM, Dooren-Greebe RJ van, Happle R, Kerkhof PCM van de. Ichthyosis bullosa of Siemens responds well to low-dosage oral retinoids. Br J Dermatol 1991; 125: 469-71.
16. Steijlen PM, Happle R, Muijen GNP van et al. Topical treatment with 13-cis-retinoic acid improves Darier's disease and induces the expression of a unique keratin pattern. Dermatologica 1991; 182: 178-83.
17. Rosenthal DS, Griffiths CE, Yuspa SH et al. Acute or chronic topical retinoic acid treatment of human skin in vivo alters the expression of epidermal transglutaminase, loricrin, involucrin, filaggrin, and keratins 6 and 13 but not keratins 1, 10, and 14. J Invest Dermatol 1992; 98: 343-50.
18. Orfanos CE, Ehlert R, Gollnick H. The retinoids, a review of their clinical pharmacology. Drugs 1987; 34: 459-503.